Gene Therapy Approaches to Improve Graft Longevity
Gene therapy is emerging as a transformative approach to enhance CABG graft durability and prevent failure. The Coronary Artery Bypass Graft Market is witnessing increased research into targeted delivery of genes that can promote endothelial function, inhibit smooth muscle proliferation, and reduce inflammation in grafted vessels.
One promising strategy involves delivering vascular endothelial growth factor (VEGF) genes to improve microvascularization within grafts. Another approach uses RNA interference to silence genes responsible for restenosis. Viral and non-viral vectors are being optimized to ensure targeted, sustained expression without triggering immune rejection.
While preclinical studies have shown positive results, clinical translation faces regulatory and safety challenges. If successful, gene therapy could dramatically extend graft lifespan, reducing the need for repeat revascularization and improving long-term survival.